REVBW
MaterialsRevelation Biosciences, Inc. Warrant
Live · NASDAQ · Mar 28, 6:08 AM
What's Moving REVBW Today?
No AI insight has been generated for REVBW yet. Check back soon — insights are generated from recent news analysis.
Generated Insights
No insights have been generated for REVBW yet. Check back soon.
REVBW News
20 articles- REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth ConferenceYahoo Finance·Mar 24, 2026
- Revelation Biosciences to Host Fireside Chat at 38th Annual Roth ConferenceYahoo Finance·Mar 19, 2026
- REVB 2026 Starts in Positive FashionYahoo Finance·Feb 27, 2026
- Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025Yahoo Finance·Feb 26, 2026
- REVB Ready to Advance Groundbreaking TreatmentYahoo Finance·Nov 7, 2025
- Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025Yahoo Finance·Nov 6, 2025
- Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record DateYahoo Finance·Oct 29, 2025
- Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025Yahoo Finance·Oct 15, 2025
- Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross ProceedsYahoo Finance·Sep 11, 2025
- Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical DataYahoo Finance·Sep 10, 2025
- Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line DataYahoo Finance·Sep 9, 2025
- Groundbreaking Results from REVB Point to Relief for MillionsYahoo Finance·Sep 9, 2025
- Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical StudyYahoo Finance·Sep 9, 2025
- REVB To Release Test Results This QuarterYahoo Finance·Aug 8, 2025
- Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025Yahoo Finance·Aug 8, 2025
- Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and ResearchYahoo Finance·Jul 24, 2025
- Revelation Biosciences Inc. Completes Dosing of Patients in PRIME StudyYahoo Finance·Jul 16, 2025
- The early winner in the 'Dexit' war for corporate relocations: NevadaYahoo Finance·Jul 10, 2025
- Investors Should Look at REVB as Top-Line Results ApproachYahoo Finance·Jul 9, 2025
- Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025Yahoo Finance·Jul 1, 2025
All 20 articles loaded
Price Data
Fundamentals
Trading
About Revelation Biosciences, Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.